Amprion announced last week its test to detect prion biomarkers for the diagnosis of Parkinson's disease received FDA's breakthrough device designation.
The San Francisco-based company said it is aiming to launch FDA-approved early detection testing for Parkinson's within 18 months.
Partners in developing the technology included the Michael J. Fox Foundation for Parkinson's Research, National Institutes of Health small business programs, and McGovern Medical School at the University of Texas Health Science Center at Houston.
Alcohol and Parkinsons 
